{"title":"纳米医学“老口新粮”:治疗新冠肺炎的新方法","authors":"F. Dorkoosh, S. Handali, I. Haririan, M. Vaziri","doi":"10.2174/2210303112666220829125054","DOIUrl":null,"url":null,"abstract":"\n\nCoronavirus disease (COVID-19) is an infectious disease caused by coronavirus. Developing specific drugs for inhibiting replication and viral entry is crucial. Several clinical trial studies\nare underway to evaluate the efficacy of anti-viral drugs for COVID-19 patients. Nanomedicine\nformulations can present a novel strategy for targeting the virus life cycle. Nano-drug delivery systems can modify the pharmacodynamics and pharmacokinetics properties of anti-viral drugs and reduce their adverse effects. Moreover, nanocarriers can directly exhibit anti-viral effects. A number\nof nanocarriers have been studied for this purpose, including liposomes, dendrimers, exosomes and\ndecoy nanoparticles (NPs). Among them, decoy NPs have been considered more as nanodecoys can\nefficiently protect host cells from the infection of SARS-CoV-2. The aim of this review article is to\nhighlight the probable nanomedicine therapeutic strategies to develop anti-viral drug delivery systems for the treatment of COVID-19.\n","PeriodicalId":11310,"journal":{"name":"Drug Delivery Letters","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Nanomedicine “New Food for an Old Mouth”: Novel Approaches for the\\nTreatment of COVID-19\",\"authors\":\"F. Dorkoosh, S. Handali, I. Haririan, M. Vaziri\",\"doi\":\"10.2174/2210303112666220829125054\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n\\nCoronavirus disease (COVID-19) is an infectious disease caused by coronavirus. Developing specific drugs for inhibiting replication and viral entry is crucial. Several clinical trial studies\\nare underway to evaluate the efficacy of anti-viral drugs for COVID-19 patients. Nanomedicine\\nformulations can present a novel strategy for targeting the virus life cycle. Nano-drug delivery systems can modify the pharmacodynamics and pharmacokinetics properties of anti-viral drugs and reduce their adverse effects. Moreover, nanocarriers can directly exhibit anti-viral effects. A number\\nof nanocarriers have been studied for this purpose, including liposomes, dendrimers, exosomes and\\ndecoy nanoparticles (NPs). Among them, decoy NPs have been considered more as nanodecoys can\\nefficiently protect host cells from the infection of SARS-CoV-2. The aim of this review article is to\\nhighlight the probable nanomedicine therapeutic strategies to develop anti-viral drug delivery systems for the treatment of COVID-19.\\n\",\"PeriodicalId\":11310,\"journal\":{\"name\":\"Drug Delivery Letters\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-08-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drug Delivery Letters\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/2210303112666220829125054\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Delivery Letters","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/2210303112666220829125054","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
Nanomedicine “New Food for an Old Mouth”: Novel Approaches for the
Treatment of COVID-19
Coronavirus disease (COVID-19) is an infectious disease caused by coronavirus. Developing specific drugs for inhibiting replication and viral entry is crucial. Several clinical trial studies
are underway to evaluate the efficacy of anti-viral drugs for COVID-19 patients. Nanomedicine
formulations can present a novel strategy for targeting the virus life cycle. Nano-drug delivery systems can modify the pharmacodynamics and pharmacokinetics properties of anti-viral drugs and reduce their adverse effects. Moreover, nanocarriers can directly exhibit anti-viral effects. A number
of nanocarriers have been studied for this purpose, including liposomes, dendrimers, exosomes and
decoy nanoparticles (NPs). Among them, decoy NPs have been considered more as nanodecoys can
efficiently protect host cells from the infection of SARS-CoV-2. The aim of this review article is to
highlight the probable nanomedicine therapeutic strategies to develop anti-viral drug delivery systems for the treatment of COVID-19.